Table 3 Characteristics of study population by serostatus trajectory
AMA-1 (N = 681) | ||||||||
|---|---|---|---|---|---|---|---|---|
000 (N = 314) | 001 (N = 40) | 010 (N = 12) | 100 (N = 47) | 011 (N = 7) | 101 (N = 33) | 110 (N = 9) | 111 (N = 219) | |
Age at baseline | ||||||||
Mean (SD) | 5.21 (7.20) | 11.52 (17.13) | 14.18 (16.01) | 17.48 (15.71) | 16.79 (24.50) | 24.35 (17.34) | 30.33 (18.41) | 26.59 (14.93) |
Gender | ||||||||
Male | 147 (46.8%) | 21 (52.5%) | 2 (16.7%) | 17 (36.2%) | 3 (42.9%) | 14 (42.4%) | 4 (44.4%) | 59 (26.9%) |
Female | 167 (53.2%) | 19 (47.5%) | 10 (83.3%) | 30 (63.8%) | 4 (57.1%) | 19 (57.6%) | 5 (55.6%) | 160 (73.1%) |
Infected at any time point | ||||||||
N (%) | 41 (13.1%) | 10 (25.0%) | 3 (25.0%) | 6 (12.8%) | 5 (71.4%) | 8 (24.2%) | 0 (0.0%) | 69 (31.5%) |
MSP-1 (N = 686) | ||||||||
|---|---|---|---|---|---|---|---|---|
000 (N = 342) | 001 (N = 75) | 010 (N = 17) | 100 (N = 43) | 011 (N = 25) | 101 (N = 34) | 110 (N = 9) | 111 (N = 141) | |
Age at baseline | ||||||||
Mean (SD) | 10.18 (12.70) | 10.49 (15.41) | 6.81 (9.89) | 13.81 (14.60) | 7.64 (9.89) | 20.40 (17.16) | 34.94 (19.73) | 28.50 (15.14) |
Gender | ||||||||
Male | 152 (44.4%) | 36 (48.0%) | 8 (47.1%) | 17 (39.5%) | 11 (44.0%) | 11 (32.4%) | 3 (33.3%) | 34 (24.1%) |
Female | 190 (55.6%) | 39 (52.0%) | 9 (52.9%) | 26 (60.5%) | 14 (56.0%) | 23 (67.6%) | 6 (66.7%) | 107 (75.9%) |
Infected at any time point | ||||||||
N (%) | 45 (13.2%) | 28 (37.3%) | 8 (47.1%) | 5 (11.6%) | 8 (32.0%) | 5 (14.7%) | 2 (22.2%) | 43 (30.5%) |